Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab

Completed

• Conditions: Diabetic Macular Edema
• Interventions: Drug: Intravitreal Injection of Aflibercept

• Registration Number: NCT02000102
• Lead Sponsor: Stanford University

Brief Summary

Patients with diabetic macular edema who were switched to aflibercept after having been treated with bevacizumab or ranibizumab were retrospectively reviewed to assess for visual acuity and anatomic outcomes.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-09
• Study First Submitted: 2013-11-26
• Study First Submitted QC: 2013-11-26
• Study First Posted: 2013-12-03
• Primary Completion: 2014-09
• Study Completion: 2014-09
• Status Verified: 2014-11
• Last Update Submitted: 2014-11-17
• Last Update Posted: 2014-11-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 14

Inclusion Criteria

Those patients with diabetic macular edema switched to aflibercept from bevacizumab and/or ranibizumab -

Read More

Exclusion Criteria

None

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Diabetic Macular Edema Patients Switched to Aflibercept	Intravitreal Injection of Aflibercept	-

Primary Outcome Measures

Name	Time	Method
Visual Acuity	1 year

Secondary Outcome Measures

Name	Time	Method
Central Subfield Thickness on Optical Coherence Tomography	1 year

Trial Locations

Locations (1)

Byers Eye Institute at Stanford; 🇺🇸 Palo Alto, California, United States